G-HOPE-001: Arcotatug tavatecan significantly improves PFS and OS in previously treated CLDN18.2-positive gastric/GEJ adenocarcinoma

EHA 2026

Multiple Myeloma (MM)

MajesTEC-9: Teclistamab significantly improves PFS and OS versus standard therapies in patients with RRMM

Gastrointestinal Cancer

Anbenitamab in previously treated HER2-positive gastric cancer (KC-WISE): pre-specified interim analysis of a randomized, phase III clinical trial

Ann Oncol

Liu R, Zhao J, Zhang R, Liu B, Liu Y, Li S, Chen Y, Yang H, Liu Z, Li Z, Qin Y, Huang M, Ba Y, Zhang H, Qu Y, Du Y, Deng T, Yang M, Hou X, Liu C, Ning F, Liu YP, Wu X, Xie Y, An Y, Zou K, She L, Xu J

doi: 10.1016/j.annonc.2026.01.006

CHICAGO 2026

Lung, Respiratory and Thoracic Cancer

LBA4: HARMONi-6: Ivonescimab plus chemotherapy significantly improved OS versus tislelizumab plus chemotherapy in previously untreated advanced squamous NSCLC

EHA 2026

Multiple Myeloma (MM)

MonumenTAL-3: Talquetamab-daratumumab regimens significantly improve PFS in patients with RRMM

ESMO 2026

Skin Cancer

LBA1: INTerpath-001: Intismeran autogene plus pembrolizumab significantly improves RFS and DMFS in resected stage IIB–IV melanoma

EHA 2026

Lymphoma

frontMIND: Tafasitamab plus lenalidomide and R-CHOP improves PFS in previously untreated high-risk DLBCL

CHICAGO 2026

Multiple Myeloma (MM)

SUCCESSOR-2: Addition of mezigdomide to Kd improves PFS and response rates in patients with RRMM

EHA 2026

Lymphoma

EPCORE DLBCL-1: Epcoritamab significantly improves PFS in patients with R/R LBCL

Breast Cancer

Tucatinib and trastuzumab emtansine for patients with previously treated HER2-positive locally advanced and metastatic breast cancer: primary analysis of the randomized phase III trial HER2CLIMB-02

Ann Oncol

Hurvitz SA, Loi S, O'Shaughnessy J, Okines AFC, Tolaney SM, Sohn J, Saura C, Zhu X, Cameron D, Bachelot T, Hamilton E, Curigliano G, Wolff AC, Harbeck N, Masuda N, Vahdat L, Zaman K, Valdes-Albini F, Block M, Pluard T, Tan TJ, Gawryletz C, Chan A, Bedard PL, Yerushalmi R, Xu B, Schmitt M, Xie D, Borges VF, HER2CLIMB-02 study investigators

doi: 10.1016/j.annonc.2025.11.005

Related content

MajesTEC-9: Teclistamab significantly improves PFS and OS versus standard therapies in patients with RRMM

Anbenitamab in previously treated HER2-positive gastric cancer (KC-WISE): pre-specified interim analysis of a randomized, phase III clinical trial

LBA4: HARMONi-6: Ivonescimab plus chemotherapy significantly improved OS versus tislelizumab plus chemotherapy in previously untreated advanced squamous NSCLC

MonumenTAL-3: Talquetamab-daratumumab regimens significantly improve PFS in patients with RRMM

LBA1: INTerpath-001: Intismeran autogene plus pembrolizumab significantly improves RFS and DMFS in resected stage IIB–IV melanoma

frontMIND: Tafasitamab plus lenalidomide and R-CHOP improves PFS in previously untreated high-risk DLBCL

SUCCESSOR-2: Addition of mezigdomide to Kd improves PFS and response rates in patients with RRMM

EPCORE DLBCL-1: Epcoritamab significantly improves PFS in patients with R/R LBCL

Tucatinib and trastuzumab emtansine for patients with previously treated HER2-positive locally advanced and metastatic breast cancer: primary analysis of the randomized phase III trial HER2CLIMB-02